Can the BeatMove Device Help Patients With Obliterative Arterial Disease of the Lower Limbs?
Evaluation of the Value of Music Therapy (BeatMove Device) in a 3-month Outpatient Walking Rehabilitation Programme for Patients With Obliterative Arterial Disease of the Lower Limbs (AOMI) at the Stress Ischaemia Stage.
Centre Hospitalier Universitaire de Nīmes
54 participants
Jun 14, 2024
INTERVENTIONAL
Conditions
Summary
Vascular rehabilitation for arteriopathy of the lower limbs remains little known in France, despite its good results. There are very few rehabilitation centres, and they are overcrowded and expensive. Outpatient walking rehabilitation is under-used, despite recommendations (4). One of the difficulties is getting patients to adhere to the treatment sufficiently and for a long time. According to the Fédération Française de Musicothérapie (FFM), this is a care practice based on sound or musical mediation with the aim of supporting, accompanying or re-educating a patient. Music is used as a means of expression, communication, structuring and relational analysis.The benefits of music therapy for our bodies and our behavior are numerous, including improvements in cognitive functions (attention, memory), psychomotor functions (agility, mobility, coordination) and social-emotional functions (healthymind website 10/03/2021).
Eligibility
Inclusion Criteria7
- Patient with stage II arterial obliteration of the lower limbs (Leriche and Fontaine classification) with exertional claudication
- Systolic Pressure Index at the toe \< 0.7 but absolute value \> 30 mmHg
- Steno-occlusive lesions on arterial Doppler ultrasound examination of the lower limbs
- Patient on an optimised vasculoprotective medical treatment (statin, antiplatelet agent, ACE inhibitor/ARB II)
- Patient who is a beneficiary or entitled beneficiary of a health insurance scheme
- Patient able to understand, write and read French
- Patient who has given free and informed consent
Exclusion Criteria10
- Patients using walking aids (cane, wheelchair)
- Amputation
- Patient with a walking perimeter \< 150 m
- Hearing or visual impairment
- Chronic ischaemia
- Trophic disorders
- Orthopaedic or vascular MI surgery planned within 3 months
- Major cardiovascular co-morbidities (MI \< 3 months or unstable angina)
- Pregnant, breast-feeding or parturient women
- Patients under court protection, guardianship or curatorship.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
Ambulatory gait training program with performance monitoring via an app, combined with sham music therapy (BeatMove device). The program includes 36 gait training sessions, each lasting 30 minutes. Patients will complete three walking sessions per week for three months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06226844